Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP0533 in AML or MDS
NCT05673057Phase 1Completed
- Sponsor
- Molecular Partners AG
- Start
- Dec 2022
- Primary completion
- May 2026
- Modality
- Antibody Fragments, Multispecific Antibodies, Carrier/Scaffold Proteins
- Countries
- 4
01
Overview
Phase 1, open-label trial of MP0533 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (6 arms), sponsored by Molecular Partners AG. Primary endpoints: Recommended Phase 2 Dose Regimen and/or Maximum Tolerated Dose Regimen at 4 weeks and Overall Response Rate at 3 months. Started Dec 2022; status: completed.
02
Drugs
MP0533
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05673057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673057.